Last updated: September 2, 2026
Viloxazine hydrochloride is marketed in the United States as Qelbree, a once-daily, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD). Supernus Pharmaceuticals owns and commercializes the product. Qelbree has expanded from a pediatric launch in 2021 to an adult ADHD product, giving Supernus a second major commercial franchise alongside Oxtellar XR.
The commercial outlook depends on prescription growth, payer coverage, physician adoption of nonstimulant therapy, and the duration of Qelbree’s patent protection. Qelbree is exposed to eventual generic competition through the abbreviated new drug application (ANDA) pathway, but the product has a longer commercial runway than many reformulated small-molecule products because the regulatory label covers both children and adults and the Orange Book estate includes formulation and method-of-use protection.
What is viloxazine hydrochloride and how is Qelbree used?
Viloxazine hydrochloride is a selective norepinephrine reuptake inhibitor with additional serotonergic activity. Qelbree is an extended-release capsule and is administered once daily.
The FDA approved Qelbree in April 2021 for ADHD in patients aged 6 to 17 years. In April 2022, the FDA expanded the indication to adults. The product is differentiated from stimulant ADHD drugs because it is a nonstimulant and is not classified as a controlled substance under U.S. federal law [1][2].
FDA-approved indications and dosage forms
| Attribute |
Qelbree |
| Active ingredient |
Viloxazine hydrochloride |
| Brand name |
Qelbree |
| Sponsor |
Supernus Pharmaceuticals |
| FDA pathway |
New drug application |
| Initial U.S. approval |
April 2021 |
| Adult indication |
Approved April 2022 |
| Therapeutic area |
ADHD |
| Dosage form |
Extended-release capsules |
| Administration |
Once daily |
| Controlled-substance status |
Not federally scheduled |
| Primary competitors |
Atomoxetine, guanfacine extended release, clonidine extended release, stimulant products |
The absence of controlled-substance scheduling supports prescribing in patients for whom diversion, misuse, or stimulant tolerability is a concern. Qelbree still competes against lower-cost generic atomoxetine and generic alpha-2 agonists, as well as highly established stimulant therapies.
How large is the viloxazine hydrochloride market?
Qelbree occupies a niche within the large U.S. ADHD market rather than competing as a broad replacement for stimulants. The relevant market includes more than 6 million U.S. children and adolescents reported to have received an ADHD diagnosis, together with a substantial adult population [3].
The commercial opportunity is driven by four segments:
- Patients who do not respond adequately to stimulants.
- Patients with stimulant-related adverse effects.
- Patients with diversion, misuse, or controlled-substance concerns.
- Patients whose physicians prefer a nonstimulant first-line or adjunctive option.
Qelbree’s market share remains small relative to stimulant products. Its commercial value comes from branded pricing, once-daily dosing, the adult indication, and continued prescribing in patients who cycle through multiple ADHD therapies.
Competitive positioning
| Product or class |
Generic availability |
Controlled substance |
Main competitive effect on Qelbree |
| Methylphenidate products |
Extensive |
Yes |
Strong price and prescribing competition |
| Amphetamine products |
Extensive |
Yes |
Dominant efficacy and familiarity |
| Atomoxetine |
Generic |
No |
Closest low-cost nonstimulant competitor |
| Guanfacine ER |
Generic |
No |
Competes in pediatric and combination therapy |
| Clonidine ER |
Generic |
No |
Pediatric and adjunctive competitor |
| Qelbree |
No generic equivalent marketed as of the cited period |
No |
Differentiated branded nonstimulant |
Qelbree’s principal strategic advantage is not a radically different mechanism. It is the combination of nonstimulant status, once-daily extended release, pediatric and adult labeling, and a branded commercial infrastructure.
What is the financial trajectory for viloxazine hydrochloride?
Qelbree sales increased materially after the adult indication was approved. Supernus reported Qelbree net product sales of approximately $110 million in 2023, up from approximately $66 million in 2022. The increase reflected broader prescribing, adult commercialization, and continued penetration in pediatric ADHD [4].
Qelbree remains smaller than Supernus’ established epilepsy products, but it is the company’s principal growth asset. The financial trajectory is therefore more important than the product’s current absolute revenue because incremental Qelbree sales can offset erosion in mature neurology products.
Reported Qelbree sales trajectory
| Fiscal year |
Qelbree net product sales |
Year-over-year trend |
| 2021 |
Initial launch year |
Commercial launch |
| 2022 |
Approximately $66 million |
Rapid expansion |
| 2023 |
Approximately $110 million |
Approximately 67% growth |
| 2024 onward |
Dependent on Supernus reporting period |
Adult uptake, payer access, and promotional efficiency |
Supernus’ filings describe Qelbree as a major contributor to revenue growth, but the product has not eliminated the company’s exposure to its legacy portfolio. Oxtellar XR and Trokendi XR remain significant revenue sources, creating a mixed trajectory: Qelbree growth supports expansion while older products face competition and market maturity [4].
What drives Qelbree revenue growth?
Qelbree revenue depends on prescription volume, gross-to-net deductions, patient access, and refill persistence.
The main growth drivers are:
- Adult ADHD prescribing.
- Increased awareness among physicians and patients.
- Use in patients who cannot take stimulants.
- Expansion of commercial formulary coverage.
- Improved diagnosis and treatment of ADHD.
- Once-daily administration.
- Noncontrolled status.
The main constraints are:
- Generic atomoxetine and guanfacine pricing.
- Prior authorization requirements.
- High branded copay exposure.
- Stimulant efficacy and physician familiarity.
- Discontinuation caused by tolerability or inadequate response.
- Promotional spending needed to maintain prescription growth.
For investors, prescription growth must be evaluated alongside net realized price. Gross prescription growth can overstate economic performance if payer rebates, copay assistance, and access programs increase.
When does viloxazine hydrochloride lose exclusivity?
Qelbree does not face biologic biosimilar erosion. It is a small-molecule drug, so the principal long-term threat is an ANDA-based generic approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act.
The effective generic-entry date depends on the Orange Book patent list, any pediatric exclusivity, Paragraph IV litigation, regulatory stays, settlement agreements, and the timing of final ANDA approval. The relevant exclusivity is therefore not determined by one date alone.
Qelbree regulatory and exclusivity timeline
| Event |
Date |
| FDA approval for pediatric ADHD |
April 2021 |
| FDA approval for adult ADHD |
April 2022 |
| Five-year new chemical entity exclusivity |
Generally runs from the first approval date, subject to statutory interpretation and listed exclusivities |
| Pediatric exclusivity |
No separate six-month pediatric extension is assumed without a specific FDA grant |
| Generic pathway |
ANDA, subject to Orange Book patent certifications |
| Biosimilar pathway |
Not applicable |
Qelbree’s first approval in 2021 established the primary five-year new chemical entity exclusivity period. That period does not prevent all later regulatory activity indefinitely, but it generally delays ANDA approval based on the new chemical entity until the statutory period has elapsed, subject to the product’s patent and exclusivity record [1][5].
Patent terms can extend beyond regulatory exclusivity. The practical entry date is usually controlled by the latest enforceable patent that an ANDA applicant must address.
What patents protect Qelbree and viloxazine hydrochloride?
Qelbree’s protection is based on patents covering viloxazine formulations, dosing, and therapeutic use. Publicly available FDA Orange Book records have identified Qelbree patent listings including U.S. Patent Nos. 10,765,667 and 11,174,276. Patent status, expiry dates, and any later listings should be confirmed against the current FDA Orange Book because listings can change through patent certifications, delistings, corrections, or new grants [5].
Principal patent categories
Formulation patents
Formulation claims are commercially important because Qelbree is an extended-release dosage form. Such claims can cover release profiles, excipient combinations, coating systems, particle characteristics, or dosage forms that deliver viloxazine over a defined period.
A generic applicant may attempt to design around a formulation patent while still demonstrating bioequivalence. The commercial strength of formulation protection depends on claim breadth and whether the generic product must use a technically similar release architecture.
Method-of-use patents
Method-of-use protection may cover treatment of ADHD with viloxazine, including patient populations, dosing schedules, or therapeutic administration. These patents can create litigation risk even where a generic applicant seeks approval for a narrower label.
A generic company may file a section viii statement carving out a patented method from its proposed label. Whether that approach is practical depends on the scope of the listed use and the FDA-approved labeling.
Manufacturing and process protection
Manufacturing patents can cover synthesis, purification, particle engineering, or production of the extended-release product. Process patents are less likely than formulation patents to block a conventional ANDA launch if the generic manufacturer can use a noninfringing process, but they can increase development costs and litigation exposure.
Patent-estate assessment
| Factor |
Assessment |
| Active ingredient |
Mature small molecule |
| Regulatory exclusivity |
Limited-duration protection from first approval |
| Formulation protection |
Commercially relevant for the extended-release product |
| Method-of-use protection |
Relevant to ADHD labeling and carve-out strategy |
| Manufacturing protection |
Potential secondary barrier |
| Biosimilar exposure |
None |
| Generic exposure |
High over the long term |
| Immediate generic threat |
Dependent on ANDA filings and Orange Book certifications |
| Litigation visibility |
Must be monitored through FDA and federal court records |
The strongest practical protection is likely to come from the combination of formulation claims, use claims, and regulatory delay rather than from the underlying viloxazine molecule alone.
What is the Orange Book status of Qelbree?
Qelbree is listed in the FDA Orange Book as a prescription drug approved through a new drug application. Orange Book listings identify patents and regulatory exclusivities that an ANDA applicant must address.
An ANDA applicant generally certifies that:
- No patent information has been filed.
- The patent has expired.
- The applicant will not market until patent expiry.
- The patent is invalid or not infringed.
- The applicant will carve out a patented method of use.
A Paragraph IV certification can trigger patent litigation if the branded sponsor files suit within the statutory period. Such litigation can produce a 30-month stay of FDA approval, although the timing and effect depend on the filing date, patent, ANDA status, and court proceedings [5][6].
Paragraph IV and generic-launch risk
As of the cited public records, Qelbree’s generic risk should be analyzed through four indicators:
- Whether an ANDA has been publicly identified.
- Whether an applicant has filed a Paragraph IV certification.
- Whether Supernus has filed an infringement complaint.
- Whether a settlement or license permits an earlier launch.
A lack of publicly reported litigation does not establish that no ANDA has been filed. ANDA filings are often confidential until litigation begins or the FDA publishes related information.
Which companies are challenging viloxazine hydrochloride?
Qelbree is marketed by Supernus Pharmaceuticals. Public commercial competition comes primarily from generic manufacturers of atomoxetine, guanfacine ER, and clonidine ER, plus branded and generic stimulant manufacturers.
Potential ANDA challengers would most likely include large generic companies with ADHD portfolios, although an applicant’s identity is not necessarily public before litigation. No specific challenger should be treated as confirmed without a court complaint, FDA notice, or company disclosure.
The competitive landscape includes:
- Teva Pharmaceutical Industries.
- Viatris.
- Sandoz.
- Amneal Pharmaceuticals.
- Lupin.
- Prasco and other authorized-generic or branded-generic channels.
- Specialty and retail pharmacy distributors supporting stimulant and nonstimulant products.
These companies compete with Qelbree today through alternative ADHD products. They do not necessarily represent confirmed Qelbree ANDA filers.
What patent litigation affects Qelbree?
A confirmed patent case involving Qelbree would materially change the estimated generic-entry date. The key litigation questions would be:
- Which Orange Book patent was challenged?
- Was the case filed within 45 days of a Paragraph IV notice?
- Did the case trigger a 30-month stay?
- Are formulation or method-of-use claims at issue?
- Has Supernus settled with the challenger?
- Does the settlement include a licensed entry date?
No settlement date or early generic launch date should be assumed without a public filing or company disclosure. Patent litigation risk remains a central commercial variable because Qelbree’s current value depends on maintaining branded pricing while prescription volume scales.
How strong is the viloxazine hydrochloride patent estate?
The patent estate is strategically meaningful but not equivalent to composition-of-matter protection for a newly discovered molecule. Viloxazine was previously marketed in Europe as an antidepressant, which limits the novelty value of the active ingredient itself. Qelbree’s protection therefore relies heavily on the modern extended-release product, ADHD use, dosing, and related formulation technology.
Strengths
- FDA approval for both pediatric and adult ADHD.
- Extended-release formulation claims.
- Multiple potential patent categories.
- Noncontrolled status that supports differentiated prescribing.
- Regulatory exclusivity from the 2021 approval.
- Commercial momentum before generic entry.
Weaknesses
- Mature active pharmaceutical ingredient.
- Generic alternatives already available in the nonstimulant class.
- Potential for formulation design-around.
- Method-of-use carve-out strategies.
- Dependence on payer coverage and branded economics.
- No biosimilar-style complexity barrier.
The estate is best characterized as moderate in composition-of-matter strength and potentially stronger in formulation and regulatory protection. Its commercial durability depends on whether generic applicants can establish bioequivalence using a noninfringing extended-release design.
What geographic coverage does viloxazine hydrochloride have?
Qelbree’s principal commercial market is the United States. Supernus has emphasized U.S. commercialization, and the product’s financial contribution is primarily tied to U.S. prescription demand and reimbursement.
International coverage is less certain because viloxazine has an older European history and regulatory, commercial, and patent rights may differ by jurisdiction. U.S. Orange Book protection does not automatically establish enforceable rights in Europe, Canada, Japan, or other markets.
Geographic risk analysis should distinguish:
- U.S. product patents.
- National and regional formulation patents.
- Regulatory exclusivity in each market.
- Local marketing authorization.
- License or distribution arrangements.
- National generic approval standards.
What manufacturing and intellectual-property barriers affect generic entry?
A generic applicant must show pharmaceutical equivalence and bioequivalence to Qelbree. Extended-release products can present more complex development requirements than immediate-release tablets because release kinetics, food effects, pharmacokinetic parameters, and formulation composition must be controlled.
Potential barriers include:
- Reproducing the extended-release profile.
- Demonstrating bioequivalence across relevant strengths.
- Avoiding formulation-patent claims.
- Addressing method-of-use patents.
- Establishing a noninfringing manufacturing process.
- Meeting FDA requirements for labeling carve-outs.
- Managing supply-chain and controlled-quality requirements.
These barriers can delay entry but rarely prevent generic competition permanently. The likely outcome is a period of patent litigation or settlement followed by price erosion once a therapeutically substitutable product launches.
What generic launch scenarios exist for Qelbree?
Scenario 1: No early Paragraph IV challenge
Generic entry occurs after the principal patent and regulatory barriers expire. This scenario provides the longest branded revenue runway but is less likely to remain uncontested as Qelbree sales increase.
Scenario 2: Paragraph IV litigation with delayed entry
An ANDA applicant challenges one or more listed patents. Supernus files suit, triggering a possible 30-month stay. Qelbree retains branded sales during litigation, but legal costs increase and the market begins discounting future erosion.
Scenario 3: Settlement with licensed early entry
Supernus and an ANDA applicant agree on an entry date before the latest patent expiry. The settlement may include authorized-generic rights, supply terms, or restrictions on launch timing. Revenue erosion begins earlier but becomes more predictable.
Scenario 4: Formulation design-around
A generic company develops a noninfringing extended-release formulation and pursues approval through an ANDA. This scenario weakens formulation-based protection and increases the importance of method-of-use patents and regulatory exclusivity.
How does Qelbree compare with atomoxetine?
Qelbree has a branded, once-daily, noncontrolled profile similar to atomoxetine but lacks atomoxetine’s generic price advantage. Atomoxetine has extensive clinical familiarity and broad insurance access. Qelbree competes by offering a newer treatment option and a distinct pharmacologic profile.
| Factor |
Qelbree |
Atomoxetine |
| Status |
Branded |
Predominantly generic |
| Class |
Nonstimulant |
Nonstimulant |
| FDA ADHD population |
Children, adolescents, adults |
Children, adolescents, adults |
| Price position |
Branded premium |
Low-cost generic |
| Controlled substance |
No |
No |
| Commercial risk |
Future ANDA erosion |
Existing generic erosion |
| Differentiation |
Newer product and formulation |
Established clinical history |
Qelbree must demonstrate enough clinical and practical value to justify its premium over generic atomoxetine. Payer restrictions remain a key variable.
What is the investment outlook for viloxazine hydrochloride?
Qelbree has a favorable growth profile within Supernus’ portfolio because it entered the market before reaching adult-label maturity. Its near-term value is tied to continued prescription growth and the ability to improve reimbursement without excessive promotional spending.
The principal valuation risks are:
- Slower adult adoption.
- Weak refill persistence.
- Limited formulary coverage.
- Generic competition from atomoxetine.
- An early Paragraph IV challenge.
- Patent invalidity or noninfringement findings.
- Settlement-based entry before the expected patent horizon.
- Revenue concentration within Supernus’ small product portfolio.
The principal upside factors are:
- Continued adult ADHD expansion.
- Increased use in stimulant-intolerant patients.
- Broader commercial insurance coverage.
- Stronger physician adoption of noncontrolled therapy.
- Patent protection extending beyond regulatory exclusivity.
- Improved operating leverage as sales scale.
Key Takeaways
- Viloxazine hydrochloride is marketed in the U.S. as Qelbree by Supernus Pharmaceuticals.
- FDA approval covers ADHD in children, adolescents, and adults.
- Qelbree net product sales rose from approximately $66 million in 2022 to approximately $110 million in 2023.
- The product is a growth asset within Supernus’ portfolio, but legacy neurology products remain financially important.
- Qelbree faces generic, not biosimilar, competition.
- The patent estate centers on extended-release formulation, dosing, and method-of-use protection rather than a new-molecule composition patent.
- Orange Book patents and any Paragraph IV litigation will determine the practical generic-entry timeline.
- Generic atomoxetine is Qelbree’s closest low-cost nonstimulant competitor.
- The commercial outlook is positive before generic entry but sensitive to payer access, adult uptake, and patent durability.
FAQs
Is viloxazine hydrochloride a stimulant?
No. Viloxazine hydrochloride is a nonstimulant ADHD treatment and is not federally scheduled as a controlled substance.
Is Qelbree available as a generic?
A generic version should not be assumed to be commercially available without confirmation from FDA approval records and current market listings. Qelbree remains the branded reference product for viloxazine extended-release capsules.
Does Qelbree have orphan-drug exclusivity?
Qelbree is approved for ADHD, not an orphan indication. Its main regulatory protection comes from new chemical entity exclusivity, pediatric or other applicable exclusivity if granted, and listed patents.
Can a generic company launch viloxazine before Qelbree patents expire?
Only if it obtains approval after resolving the relevant patent certifications, prevails in litigation, reaches a settlement with Supernus, or develops a product that avoids enforceable patent claims and other regulatory barriers.
Is viloxazine hydrochloride marketed outside the United States?
Viloxazine was previously marketed in Europe as an antidepressant, but the current commercial and patent analysis for Qelbree is primarily U.S.-focused. International regulatory approvals and patent rights must be assessed separately.
References
-
U.S. Food and Drug Administration. (2021). Qelbree (viloxazine hydrochloride) extended-release capsules: Initial U.S. approval and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2022). FDA approves Qelbree for adults with attention deficit hyperactivity disorder. FDA.
-
Centers for Disease Control and Prevention. (2024). Data and statistics about ADHD. U.S. Department of Health and Human Services.
-
Supernus Pharmaceuticals, Inc. (2024). 2023 annual report on Form 10-K. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book: Qelbree. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
